Peixuan Guo

Prof. Peixuan Guo

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2017 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
FPFengmei Pi
Fengmei Pi
DBDaniel W. Binzel
Daniel W. Binzel
TLTae Jin Lee
Tae Jin Lee
ZLZhefeng Li
Zhefeng Li
MSMeiyan Sun
Meiyan Sun
Peixuan GuoPeixuan Guo
Peixuan Guo
Nanotechnology offers many benefits, and here we report an advantage of applying RNA nanotechnology for directional control. The orientation of arrow-shaped RNA was altered to control ligand display on extracellular vesicle membranes for specific cell targeting, or to regulate intracellular trafficking of small interfering RNA (siRNA) or microRNA (miRNA). Placing membrane-anchoring cholesterol at the tail of the arrow results in display of RNA aptamer or folate on the outer surface of the extracellular vesicle. In contrast, placing the cholesterol at the arrowhead results in partial loading of RNA nanoparticles into the extracellular vesicles. Taking advantage of the RNA ligand for specific targeting and extracellular vesicles for efficient membrane fusion, the resulting ligand-displaying extracellular vesicles were capable of specific delivery of siRNA to cells, and efficiently blocked tumour growth in three cancer models. Extracellular vesicles displaying an aptamer that binds to prostate-specific membrane antigen, and loaded with survivin siRNA, inhibited prostate cancer xenograft. The same extracellular vesicle instead displaying epidermal growth-factor receptor aptamer inhibited orthotopic breast cancer models. Likewise, survivin siRNA-loaded and folate-displaying extracellular vesicles inhibited patient-derived colorectal cancer xenograft.

7 February 2017 in ACS Nano
Verified
Journal Article
Open access
DJDaniel Jasinski
Daniel Jasinski
FHFarzin Haque
Farzin Haque
DBDaniel W Binzel
Daniel W Binzel
Peixuan GuoPeixuan Guo
Peixuan Guo
The field of RNA nanotechnology has advanced rapidly during the last decade. A variety of programmable RNA nanoparticles with defined shape, size, and stoichiometry have been developed for diverse applications in nanobiotechnology. The rising popularity of RNA nanoparticles is due to a number of factors: (1) Removing the concern of RNA degradation in vitro and in vivo by introducing chemical modification into nucleotides without significant alteration of the RNA property in folding and self-assembly; (2) Confirming the concept that RNA displays very high thermodynamic stability and is suitable for in vivo trafficking and other applications; (3) Obtaining the knowledge to tune the immunogenic properties of synthetic RNA constructs for in vivo applications; (4) Increased understanding of the 4D structure and intermolecular interaction of RNA molecules; (5) Developing methods to control shape, size and stoichiometry of RNA nanoparticles; (6) Increasing knowledge of unique regulation and processing functions of RNA in cells; (7) Decreasing cost of RNA production by biological and chemical synthesis; and (8) Proving the concept that RNA is a safe and specific therapeutic modality for cancer and other diseases with little or no accumulation in vital organs. Other applications of RNA nanotechnology, such as adapting them to construct 2D, 3D and 4D structures for use in tissue engineering, biosensing, resistive biomemory, and potential computer logic gate modules, have stimulated the interest of the scientific community. This review aims to outline the current state of the art of RNA nanoparticles as programmable smart complexes, and offer perspectives on the promising avenues of research on this fast-growing field.

2 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZLZhefeng Li
Zhefeng Li
HWHongzhi Wang
Hongzhi Wang
HYHongran Yin
Hongran Yin
CBChad Bennett
Chad Bennett
HZHuang-Ge Zhang
Huang-Ge Zhang
Peixuan GuoPeixuan Guo
Peixuan Guo
Exosomes have shown increasing potential as delivery vesicles for therapy, but challenges like cost/yield, drug payload, and targeting specificity still exist. Plant derived exosome-like nanoparticles have been reported as a promising substitution and exhibit biocompatibility through oral, intranasal administration; however, systemic delivery of siRNA by exosome-like nanoparticles directly isolated from plants has not been reported. Recently, we reported the control of RNA orientation to decorate human derived exosome with cell targeting ligands for specific delivery of siRNA to tumors. Here, we expand to the application of arrowtail RNA nanoparticles for displaying ligands on ginger derived exosome-like nanovesicles (GDENs) for siRNA delivery and tumor inhibition through IV administration. Cushion ultracentrifugation coupled with equilibrium density gradient ultracentrifugation were used for purifying GDENs that displayed size, density, and morphology similar to human derived exosomes. Folic acid (FA), as a ligand, was displayed on the surface of GDENs for targeted delivery of survivin siRNA to KB cancer models. In vitro gene knockdown efficacy by FA-3WJ/GDENs/siRNA complex was comparable to transfection. We observed inhibition of tumor growth on a xenograft model by intravenous administration, which reveals the potential of GDENs as an economic delivery system for siRNA.

1 July 2019 in Molecular Therapy
Verified
Journal Article
Open access
HYHongran Yin
Hongran Yin
GXGaofeng Xiong
Gaofeng Xiong
SGSijin Guo
Sijin Guo
CXCongcong Xu
Congcong Xu
RXRen Xu
Ren Xu
DSDan Shu
Dan Shu
Triple-negative breast cancer (TNBC) is an aggressive disease with a short median time from relapse to death. The increased aggressiveness, drug resistance, disease relapse, and metastasis are associated with the presence of stem cells within tumors. Several stem cell markers, such as CD24, CD44, CD133, ALDH1, and ABCG2, have been reported, but their roles in breast cancer tumorigenesis remain unclear. Herein, we apply RNA nanotechnology to deliver anti-microRNA (miRNA) for TNBC therapy. The thermodynamically and chemically stable three-way junction (3WJ) motif was utilized as the scaffold to carry an RNA aptamer binding to CD133 receptor and a locked nuclei acid (LNA) sequence for miRNA21 inhibition. Binding assays revealed the specific uptake of the nanoparticles to breast cancer stem cells (BCSCs) and TNBC cells. Functional assays showed that cancer cell migration was reduced, miR21 expression was inhibited, and downstream tumor suppressor PTEN and PDCD4 expressions were upregulated. In vitro and in vivo studies revealed that these therapeutic RNA nanoparticles did not induce cytokine secretion. Systemic injection of these RNA nanoparticles in animal trial demonstrated high specificity in TNBC tumor targeting and high efficacy for tumor growth inhibition. These results revealed the clinical translation potential of these RNA nanoparticles for TNBC therapy.

20 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SGSijin Guo
Sijin Guo
MVMario Vieweger
Mario Vieweger
KZKaiming Zhang
Kaiming Zhang
HYHongran Yin
Hongran Yin
HWHongzhi Wang
Hongzhi Wang
Peixuan GuoPeixuan Guo
Peixuan Guo
Paclitaxel is widely used in cancer treatments, but poor water-solubility and toxicity raise serious concerns. Here we report an RNA four-way junction nanoparticle with ultra-thermodynamic stability to solubilize and load paclitaxel for targeted cancer therapy. Each RNA nanoparticle covalently loads twenty-four paclitaxel molecules as a prodrug. The RNA-paclitaxel complex is structurally rigid and stable, demonstrated by the sub-nanometer resolution imaging of cryo-EM. Using RNA nanoparticles as carriers increases the water-solubility of paclitaxel by 32,000-fold. Intravenous injections of RNA-paclitaxel nanoparticles with specific cancer-targeting ligand dramatically inhibit breast cancer growth, with nearly undetectable toxicity and immune responses in mice. No fatalities are observed at a paclitaxel dose equal to the reported LD 50 . The use of ultra-thermostable RNA nanoparticles to deliver chemical prodrugs addresses issues with RNA unfolding and nanoparticle dissociation after high-density drug loading. This finding provides a stable nano-platform for chemo-drug delivery as well as an efficient method to solubilize hydrophobic drugs.

1 October 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
ZZZhen Zheng
Zhen Zheng
ZLZhefeng Li
Zhefeng Li
CXCongcong Xu
Congcong Xu
BGBin Guo
Bin Guo
Peixuan GuoPeixuan Guo
Peixuan Guo